XY-14 is a competitive inhibitor of Lipid Phosphate Phosphatase 1 (LPP1) which is the major enzyme responsible for degrading lysophosphatidic acid (LPA) in platelets. XY-14 (10 μM) inhibits LPP1 in human pulmonary artery endothelial cells, preventing the dephosphorylation of sphingosine 1-phosphate (S1P) to sphingosine. XY-14 is also reported to inhibit LPP2 & LPP3 (1).
XY-14 (Lipid Phosphate Phosphatase 1 Inhibitor)
Product Number: L-9218
$471.45 – $897.75
Inhibitor, Lysophosphatidic Acid, Phosphatidic Acid
|Molecular Weight (g/mol)||
-20 °C or below
1) Smyth, S. S., V. A. Sciorra, et al. (2003). “Lipid Phosphate Phosphatases Regulate Lysophosphatidic Acid Production and Signaling in Platelets.” Journal of Biological Chemistry 278(44): 43214-43223.
2) Zhao, Y., S. K. Kalari, et al. (2007). “Intracellular Generation of Sphingosine 1-Phosphate in Human Lung Endothelial Cells: Role Of Lipid Phosphate Phosphatase-1 And Sphingosine Kinase 1.” J Biol Chem 282(19): 14165-77.
3) Lin, A., et al. (2017). “The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors.” Nat Cell Biol 19(3): 238-251.
4) Langedijk, J. A. G. M., et al. (2021). “Inhibition of autotaxin by bile salts and bile salt-like molecules increases its expression by feedback regulation.” Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease 1867(11): 166239.